Oppenheimer Reiterates Outperform on Dyne Therapeutics, Raises Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $44 to $47.

March 05, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst reiterates Outperform rating on Dyne Therapeutics and increases price target to $47.
The reiteration of an Outperform rating combined with an increased price target typically signals strong confidence in the company's future performance, potentially leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100